DGIdb - BRIVANIB Drug Record

BRIVANIB chembl:CHEMBL377300 Antineoplastic

Alternate Names:

BRIVANIB
BMS-540215

Drug Info:

Drug Class	Kinase Inhibitors

(3 More Sources)

Publications:

Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics
Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.

BRIVANIB FGFR3P1

Interaction Score: 11.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20124951

Sources:
PharmGKB
BRIVANIB FGFRL1

Interaction Score: 11.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20124951

Sources:
PharmGKB
BRIVANIB CEP43

Interaction Score: 11.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20124951

Sources:
PharmGKB
BRIVANIB FGFR1OP2

Interaction Score: 11.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20124951

Sources:
PharmGKB
BRIVANIB FGFR4

Interaction Score: 0.65

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

PMIDs:
20124951

Sources:
ChemblInteractions PharmGKB
BRIVANIB FGFR2

Interaction Score: 0.55

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Response Type decreased response

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

PMIDs:
22238366 20124951

Sources:
JAX-CKB ChemblInteractions PharmGKB
BRIVANIB FGFR3

Interaction Score: 0.45

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

Direct Interaction yes

Indication/Tumor Type Advanced Solid Tumor

PMIDs:
22238366 20124951

Sources:
JAX-CKB ChemblInteractions PharmGKB
BRIVANIB FGFR1

Interaction Score: 0.33

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type no benefit

Approval Status Preclinical

PMIDs:
22238366 20124951

Sources:
JAX-CKB ChemblInteractions PharmGKB
BRIVANIB KDR

Interaction Score: 0.27

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
20124951

Sources:
TALC MyCancerGenome ChemblInteractions PharmGKB TTD
BRIVANIB FLT1

Interaction Score: 0.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
BRIVANIB FLT4

Interaction Score: 0.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

MyCancerGenome: BRIVANIB
- Version: 20-Jun-2017
Alternate Names:

BRIVANIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:
JAX-CKB: Brivanib
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.
PharmGKB: brivanib
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics
TALC: BRIVANIB
- Version: 12-May-2016
Alternate Names:

BRIVANIB Primary Drug Name

BRIVANIB Drug Generic Name

Drug Info:

Publications:
TTD: Brivanib
- Version: 2020.06.01
Alternate Names:

D0HS5V TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL377300
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL377300
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Direct Interaction	yes
Mechanism of Interaction	Fibroblast growth factor receptor inhibitor

Response Type	decreased response
Indication/Tumor Type	Advanced Solid Tumor
Response Type	sensitive

Notes
Mechanism of Interaction	Vascular endothelial growth factor receptor inhibitor
Direct Interaction	yes

BRIVANIB	Primary Drug Name
BRIVANIB	Drug Generic Name

BRIVANIB Drug Record

BRIVANIB chembl:CHEMBL377300 Antineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20124951

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20124951

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20124951

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20124951

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Fibroblast growth factor receptor inhibitor

PMIDs: 20124951

Sources: ChemblInteractions PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Response Type decreased response Indication/Tumor Type Advanced Solid Tumor Response Type sensitive

PMIDs: 22238366 20124951

Sources: JAX-CKB ChemblInteractions PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Fibroblast growth factor receptor inhibitor Direct Interaction yes Indication/Tumor Type Advanced Solid Tumor

PMIDs: 22238366 20124951

Sources: JAX-CKB ChemblInteractions PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Indication/Tumor Type Advanced Solid Tumor Response Type no benefit Approval Status Preclinical

PMIDs: 22238366 20124951

Sources: JAX-CKB ChemblInteractions PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor Direct Interaction yes

PMIDs: 20124951

Sources: TALC MyCancerGenome ChemblInteractions PharmGKB TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

MyCancerGenome: BRIVANIB

Alternate Names: BRIVANIB Generic Name

Drug Info: Drug Class Kinase Inhibitors

Publications:

JAX-CKB: Brivanib

Alternate Names:

Drug Info:

Publications: Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.

PharmGKB: brivanib

Alternate Names:

Drug Info:

Publications: Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics

TALC: BRIVANIB

Alternate Names: BRIVANIB Primary Drug Name BRIVANIB Drug Generic Name

Drug Info:

Publications:

TTD: Brivanib

Alternate Names: D0HS5V TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL377300

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL377300

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
20124951

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20124951

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20124951

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20124951

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

PMIDs:
20124951

Sources:
ChemblInteractions PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Response Type decreased response

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

PMIDs:
22238366 20124951

Sources:
JAX-CKB ChemblInteractions PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

Direct Interaction yes

Indication/Tumor Type Advanced Solid Tumor

PMIDs:
22238366 20124951

Sources:
JAX-CKB ChemblInteractions PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type no benefit

Approval Status Preclinical

PMIDs:
22238366 20124951

Sources:
JAX-CKB ChemblInteractions PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
20124951

Sources:
TALC MyCancerGenome ChemblInteractions PharmGKB TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Alternate Names:

BRIVANIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:

Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.

Publications:

Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics

Alternate Names:

BRIVANIB Primary Drug Name

BRIVANIB Drug Generic Name

Alternate Names:

D0HS5V TTD Drug ID